Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 1.79 0.02 (1.11%)
Day High: 1.83
Day Low:  1.75
Volume:    390,300
4:00 PM ET
Nov 21, 2014

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
Nov 20, 2014 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation related to its clinical stage product candidate, OXi4503, will be presented at the American Society of Hematology (ASH) annual meeting taking place D...
Nov 17, 2014 SOUTH SAN FRANCISCO, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the company has been granted a patent by the European Patent Office related to its current clinical product candidate, OXi4503. The patent (EP 2219451 B1) is drawn to the ...
Nov 12, 2014 - Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference - - Two Phase 2 Fosbretabulin Studies Initiated in Ovarian and Gastrointestinal Neuroendocrine Tumors (GI-NETs) - SOUTH SAN FRANCISCO, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutic...
Nov 10, 2014 - Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients - - Detailed Results Presented at the International Gynecologic Cancer Society Meeting - SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cance...
Oct 22, 2014 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will hold a conference call and webcast on Wednesday, November 12, 2014 at 4:30 p.m. ET (1:30 p.m. PT). During the call, members of the OXiGENE management team will pro...
Oct 7, 2014 SOUTH SAN FRANCISCO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 1b/2 clinical study that will evaluate fosbretabulin in combination with Votrient™ (pazopanib) in patients with recurre...
Oct 6, 2014 South San Francisco, Calif., October 6, 2014 - OXiGENE, Inc. (NASDAQ:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on Sunday, November 9 at the 15th Biennial Meeting of the Internationa...
Sep 17, 2014 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 2 study to evaluate the safety and activity of fosbretabulin monotherapy in patients with locally advanced, recurrent or me...
Aug 26, 2014 SOUTH SAN FRANCISCO, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David Chaplin, Ph.D., CEO, will present a corporate overview at the Rodman and Renshaw Annual Global Investment conference on Tuesday, September 9, 2014 ...
Aug 5, 2014 - Phase 2 Trial of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors Planned - - Further Data from Gynecologic Oncology Group (GOG) Phase 2 Ovarian Cancer Trial to be Presented in November - - Cash Balance Increased to $36.3 Million - SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:O...
Page:
1
... NextLast
= add release to Briefcase